Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843782 | 1.00 | KMT2A (0.41) | KMT2ABLMALOX15PMP22MMP2 | |
| SCHEMBL10355085 | 0.86 | FOLH1 (0.50) | KMT2ABLMFOLH1RIMKLANAALAD2 | |
| SCHEMBL20154874 | 0.86 | FOLH1 (0.50) | KMT2ABLMFOLH1RIMKLANAALAD2 | |
| SCHEMBL757317 | 0.82 | ECE1 (0.40) | KMT2ACA2CA1MEN1TGFBR1 | |
| SCHEMBL24165071 | 0.80 | KMT2A (0.48) | KMT2ABLMALOX15PMP22MMP2 | |
| Phosphoric Acid SCHEMBL27542272 | 0.78 | KMT2A (0.41) | KMT2ABLMALOX15PMP22MMP2 | |
| SCHEMBL3083186 | 0.78 | CA2 (0.40) | KMT2ABLMALOX15PMP22MMP2 | |
| SCHEMBL3083184 | 0.78 | CA2 (0.40) | KMT2ABLMALOX15PMP22MMP2 | |
| SCHEMBL3334377 | 0.77 | KMT2A (0.45) | KMT2ABLMALOX15PMP22MMP2 | |
| SCHEMBL18680610 | 0.77 | KMT2A (0.45) | KMT2ABLMALOX15PMP22MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248696-A1 | LENALIDOMIDE PRODRUGS, POLYMERIC CONJUGATES, AND FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF MULTIPLE MYELOMA | DYNAMIC BIOLOGICS INC (US) | 2023-08-10 | — | — | US | claimed |
| EP-3989939-A1 | LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | Dynamic Biologics Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| US-10952970-B2 | Use of vitelline protein B as a microencapsulating additive | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-03-23 | — | — | US | claimed |
| WO-2020264460-A1 | LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE | DYNAMIC BIOLOGICS INC. (US) | 2020-12-30 | — | — | WO | claimed |
| WO-2020227183-A1 | LENALIDOMIDE PRODRUGS, POLYMERIC CONJUGATES, AND FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF MULTIPLE MYELOMA | DYNAMIC BIOLOGICS INC. (US) | 2020-11-12 | — | — | WO | claimed |
| WO-2020081116-A1 | POLYMERIC COMPOUNDS AND COMPOSITIONS OF FUMARIC ACID ESTERS AND THEIR USE IN TREATING RELAPSING–REMITTING MULTIPLE SCLEROSIS AND PSORIASIS | DYNAMIC BIOLOGICS INC. (US) | 2020-04-23 | — | — | WO | claimed |
| US-20170135958-A1 | Use of Vitelline Protein B as a Microencapsulating Additive | THE UNIVERSITY OF DELAWARE | 2017-05-18 | — | — | US | claimed |
| US-9522120-B2 | Compositions and methods of making sustained release liquid formulations | NEOS THERAPEUTICS, LP (US) | 2016-12-20 | — | — | US | claimed |
| US-9387279-B2 | Implantable-glucose responsive insulin delivery device | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-07-12 | — | — | US | claimed |
| US-20130084340-A1 | Compositions and Methods of Making Sustained Release Liquid Formulations | NEOS THERAPEUTICS, LP (US) | 2013-04-04 | — | — | US | claimed |
| EP-2164631-A1 | MODIFYING DRUG RELEASE IN SUSPENSIONS OF IONIC RESIN SYSTEMS | Neos Therapeutics, LP (US) | 2010-03-24 | — | — | EP | claimed |
| WO-2009037313-A1 | AMPHIPHILIC COPOLYMERS AND COMPOSITIONS CONTAINING SUCH POLYMERS | NIRVANA'S TREE HOUSE B.V. (NL) | 2009-03-26 | — | — | WO | claimed |
| US-20090011027-A1 | Modifying Drug Release in Suspensions of Ionic Resin Systems | NEOS THERAPEUTICS, LP (US) | 2009-01-08 | — | — | US | claimed |
| WO-2008151071-A1 | MODIFYING DRUG RELEASE IN SUSPENSIONS OF IONIC RESIN SYSTEMS | NEOS THERAPEUTICS, LP (US) | 2008-12-11 | — | — | WO | claimed |
| US-20060193877-A1 | Compositions and methods of making sustained release liquid formulations | PFAB, LP (US) | 2006-08-31 | — | — | US | claimed |
| US-20050260258-A1 | Use of vitelline protein B as a microencapsulating additive | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-11-24 | — | — | US | claimed |
| US-6565872-B2 | A composite polymer system comprising a stimuli-responsive polymer selected from R-acrylamide, R1-acryalate, R2-acrylic acid, polyethylene glycol(R,R1,R2=H or alkyl) at least one second polymer such as, polysaccharide, cellulose, polyester | Wu, Xiao Yu (CA) | 2003-05-20 | — | — | US | claimed |
| EP-0245820-B1 | Biodegradable microspheres as a carrier for macromolecules | UNIV KENTUCKY RES FOUND (US) | 1995-12-27 | — | — | EP | claimed |
| US-5160745-A | Three dimensional network, sustained release of hormones, peptides, vaccines, enzymes | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1992-11-03 | — | — | US | claimed |
| US-4741872-A | Preparation of biodegradable microspheres useful as carriers for macromolecules | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1988-05-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248696-A1 | LENALIDOMIDE PRODRUGS, POLYMERIC CONJUGATES, AND FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF MULTIPLE MYELOMA | MALT1, BCL6, BCR | KMT2A 299/4885BLM 4599/4885ALOX15 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.